Compare MATH & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | SER |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 56.4M |
| IPO Year | 2016 | 2024 |
| Metric | MATH | SER |
|---|---|---|
| Price | $1.04 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 29.1K | ★ 67.7K |
| Earning Date | 08-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.14 |
| 52 Week High | $3.19 | $4.26 |
| Indicator | MATH | SER |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 34.43 |
| Support Level | $0.93 | $1.33 |
| Resistance Level | $1.13 | $2.13 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 60.26 | 14.18 |
Metalpha Technology Holding Ltd mainly operates in the trading of proprietary digital assets and derivative contracts in Hong Kong. The Company's primary business operations center on digital asset services, offered through its subsidiaries. The Company generates income mainly from executing cryptocurrency-related transactions, including providing derivative solutions to over-the-counter (OTC) clients, issuing derivative products to OTC clients, and engaging in proprietary trading activities. The Company provides crypto derivative solutions and liquidity to its clients, facilitated through its principal trading activities, enabling seamless trading of crypto derivative solutions. The Company generates revenue from Hong Kong.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.